Symphogen Issued United States Patent Covering Symplex™ Technology for Antibody Discovery
COPENHAGEN, Denmark and PRINCETON, New Jersey 13 July, 2010)
Symphogen A/S announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 7,749,697, titled "Method for linking sequences of interest." The patent broadly covers Symphogen's SymplexTM technology, a novel PCR-based process for identifying and isolating target-specific high affinity antibodies, the starting point for discovery and development of antibody drugs customized to a particular therapeutic application. The technology allows efficient high-throughput isolation of antibodies maintaining the natural high binding affinity and specificity of the original donor antibodies. In addition to the United States patent, patents on the SymplexTM technology have been granted in numerous territories worldwide, including a European patent covering 27 countries.
Click here to read Symphogen's news release.